Pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: Review of literature

Endocrine Practice

Volumn 17, Issue SUPPL. 3, 2011, Pages 33-40

  Tonelli, Francesco ^a   Giudici, Francesco ^a   Fratini, Geri ^a   Brandi, Maria Luisa ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; GASTRINOMA; GLUCAGONOMA; HISTOPATHOLOGY; HUMAN; HYPERPARATHYROIDISM; IMAGING; INSULINOMA; LIVER METASTASIS; MALIGNANT TRANSFORMATION; MULTIPLE ENDOCRINE NEOPLASIA; PANCREAS ISLET CELL TUMOR; PARATHYROID TUMOR; PEROPERATIVE CARE; PREOPERATIVE EVALUATION; REVIEW; SOMATOSTATINOMA; SURGICAL APPROACH; VIPOMA;

EID: 84860403671     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP10376.RA     Document Type: Review

References (85)

1. Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med. 1998;129:484-494. (Pubitemid 28428085)
2. Calender A, Cadiot G, Mignon M. Multiple endocrine neoplasia type 1: genetic and clinical aspects [in French]. Gastroenterol Clin Biol. 2001;25(4 suppl):B38-B48. (Pubitemid 32679264)
3. Chanson P, Cadiot G, Murat A ([GENEM1] Groupe d'Etude des Néoplasies Endocriniennes Multiples de Type 1). Management of patients and subjects at risk for multiple endocrine neoplasia type 1: MEN 1. Horm Res. 1997;47:211-220. (Pubitemid 27196455)
4. Lemmens I, Van de Ven WJ, Kas K, et al (European Consortium on MEN1). Identifcation of the multiple endocrine neoplasia type 1 (MEN1) gene. Hum Mol Genet. 1997;6:1177-1183. (Pubitemid 27308405)
5. Doherty GM, Olson JA, Frisella MM, Lairmore TC, Wells SA Jr, Norton JA. Lethality of multiple endocrine neoplasia type I [with discussion]. World J Surg. 1998;22:581-587. (Pubitemid 28215436)
6. Doherty GM. Multiple endocrine neoplasia type 1: duode-nopancreatic tumors. Surg Oncol. 2003;12:135-143. (Pubitemid 37289018)
7. Doherty GM, Lairmore TC, DeBenedetti MK. Multiple endocrine neoplasia type 1 parathyroid adenoma development over time. World J Surg. 2004;28:1139-1142. (Pubitemid 40109865)
8. Hausman MS Jr, Thompson NW, Gauger PG, Doherty GM. The surgical management of MEN-1 pancreatoduode-nal neuroendocrine disease. Surgery. 2004;136:1205-1211. (Pubitemid 39647535)
9. Imamura M. Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. World J Gastroenterol. 2010;16:4519-4525.
10. Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004-2010.
11. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affnity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338-1347. (Pubitemid 37247950)
12. Tiling N, Ricke J, Wiedenmann B. Neuroendocrine tumors of the gastrointestinal-pancreatic system: classifcation and diagnosis [in German]. Internist (Berl). 2002;43:210-218. (Pubitemid 36132377)
13. Plöckinger U, Wiedenmann B. Neuroendocrine tumors of the gastro-entero-pancreatic system: the role of early diagnosis, genetic testing and preventive surgery. Dig Dis. 2002;20:49-60.
14. Lewis RB, Lattin GE Jr, Paal E. Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. Radiographics. 2010;30:1445-1464.
15. Pitre J, Soubrane O, Dousset B, Palazzo L, Chapuis Y. Pancreatic echo-endoscopy and preoperative localization of insulinomas [in French]. Ann Chir. 1998;52:369-373. (Pubitemid 28196209)
16. Roland CL, Lo CY, Miller BS, Holt S, Nwariaku FE. Surgical approach and perioperative complications determine short-term outcomes in patients with insuli-noma: results of a bi-institutional study. Ann Surg Oncol. 2008;15:3532-3537.
17. Pitre J, Soubrane O, Palazzo L, Chapuis Y. Endoscopic ultrasonography for the preoperative localization of insulinomas. Pancreas. 1996;13:55-60. (Pubitemid 26187770)
18. McLean A. Endoscopic ultrasound in the detection of pancreatic islet cell tumours. Cancer Imaging. 2004;4:84-91.
19. Sotoudehmanesh R, Hedayat A, Shirazian N, et al. Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine. 2007;31:238-241. (Pubitemid 47574974)
20. Tonelli F, Fratini G, Nesi G, et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastri-nomas and pancreatic endocrine neoplasias. Ann Surg. 2006;244:61-70. (Pubitemid 44297449)
21. Wong M, Isa SH, Zahiah M, Azmi KN. Intraoperative ultrasound with palpation is still superior to intra-arterial calcium stimulation test in localising insulinoma. World J Surg. 2007;31:586-592. (Pubitemid 46356068)
22. Doppman JL, Chang R, Fraker DL, et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium [published correction appears in Ann Intern Med. 1995;123:734].
23. Ann Intern Med. 1995;123:269-273.
24. Doppman JL, Miller DL, Chang R, Gorden P, Eastman RC, Norton JA. Intraarterial calcium stimulation test for detection of insulinomas. World J Surg. 1993;17:439-443. (Pubitemid 23228395)
25. Skogseid B, Oberg K, Akerström G, et al. Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: can it be predicted by preoperative tumor localization [with discussion]? World J Surg. 1998;22:673-678. (Pubitemid 28277860)
26. Fendrich V, Waldmann J, Bartsch DK, Langer P. Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol. 2009;6:419-428.
27. Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1 [with discussion]. Ann Surg. 2005;242:757-766. (Pubitemid 41714054)
28. Cadiot G, Murat A, Penfornis F, Delemer B, Waterlot C, Cardot Bauters C (GRESZE, GENEM). Evaluation prospective de la prevalence des tumeurs endocrines duo-déno-pancréatiques non fonctionnelles dans la néoplasie endocrine multiple de type 1 [abstract]. Gastroenterol Clin Biol. 2000;24:A187.
29. Oberg K, Astrup L, Eriksson B, et al (Nordic NE Tumour Group). Guidelines for the management of gas-troenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms): Part I-general overview. Acta Oncol. 2004;43:617-625. (Pubitemid 39563934)
30. Kouvaraki MA, Shapiro SE, Cote GJ, et al. Management of pancreatic endocrine tumors in multiple endocrine neo-plasia type 1. World J Surg. 2006;30:643-653. (Pubitemid 43724089)
31. Triponez F, Dosseh D, Goudet P, et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg. 2006;243:265-272. (Pubitemid 43185447)
32. Triponez F, Goudet P, Dosseh D, et al (French Endocrine Tumor Study Group). Is surgery benefcial for MEN1 patients with small (or = 2 cm), nonfunction-ing pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE [with discussion]. World J Surg. 2006,30, 654-664.
33. Gibril F, Venzon DJ, Ojeaburu JV, Bashir S, Jensen RT. Prospective study of the natural history of gastri-noma in patients with MEN1: defnition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab. 2001;86:5282-5293. (Pubitemid 33070249)
34. Skogseid B, Larsson C, Oberg K. Genetic and clinical characteristics of multiple endocrine neoplasia type 1. Acta Oncol. 1991;30:485-488.
35. Toliat MR, Berger W, Ropers HH, Neuhaus P, Wiedenmann B. Mutations in the MEN I gene in sporadic neuroendocrine tumours of gastroenteropancreatic system. Lancet. 1997;350:1223. (Pubitemid 127445099)
36. Lowney JK, Frisella MM, Lairmore TC, Doherty GM. Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size [with discussion]. Surgery. 1998;124:1043-1049. (Pubitemid 28555191)
37. Grama D, Skogseid B, Wilander E, et al. Pancreatic tumors in multiple endocrine neoplasia type 1: clinical presentation and surgical treatment [with discussion]. World J Surg. 1992;16:611-619.
38. Thompson NW. Multiple endocrine neoplasia type I: surgical therapy. Cancer Treat Res. 1997;89:407-419.
39. Bartsch DK, Langer P, Wild A, et al. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance? Surgery. 2000;128:958-966.
40. Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999; 341:635-644. (Pubitemid 29399042)
41. Ruszniewski P, Amouyal P, Amouyal G, et al. Localization of gastrinomas by endoscopic ultrasonogra-phy in patients with Zollinger-Ellison syndrome. Surgery. 1995;117:629-635.
42. Tonelli F, Fratini G, Falchetti A, Nesi G, Brandi ML. Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience. J Intern Med. 2005;257:38-49. (Pubitemid 40129125)
43. Norton JA. Endocrine tumours of the gastrointestinal tract: surgical treatment of neuroendocrine metastases. Best Pract Res Clin Gastroenterol. 2005;19:577-583.
44. Marini F, Falchetti A, Del Monte F, et al. Multiple endocrine neoplasia type 2. Orphanet J Rare Dis. 2006;1:45.
45. Lairmore TC, Moley JF. Endocrine pancreatic tumors. Scand J Surg. 2004;93:311-315. (Pubitemid 40095959)
46. Goudet P, Murat A, Binquet C, et al. Risk factors and causes of death in MEN1 disease: a GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2010;34:249-255.
47. Thompson NW. Management of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type 1. Surg Oncol Clin North Am. 1998;7:881-891. (Pubitemid 28436545)
48. Skogseid B, Oberg K, Eriksson B, et al. Surgery for asymptomatic pancreatic lesion in multiple endocrine neo-plasia type 1 [with discussion]. World J Surg. 1996;20: 872-877. (Pubitemid 26281917)
49. Grama D, Eriksson B, Mårtensson H, et al. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg. 1992;16:632-639.
50. Delcore R, Friesen SR. Role of pancreatoduodenectomy in the management of primary duodenal wall gastrinomas in patients with Zollinger-Ellison syndrome [with discussion]. Surgery. 1992;112:1016-1023. (Pubitemid 23008227)
51. Stadil F. Treatment of gastrinomas with pancreatoduo-denectomy. In: Mignon M, Jensen RT, eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Vo l 23. Frontiers of Gastrointestinal Research. Basel, Switzerland: Karger, 1995: 333-341.
52. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240:757-773. (Pubitemid 39425767)
53. Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med. 1998;243:477-488. (Pubitemid 28312244)
54. Cadiot G, Vuagnat A, Doukhan I, et al (Groupe d'Etude des Néoplasies Endocriniennes Multiples [GENEM] and Groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison [GRESZE]). Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Gastroenterology. 1999;116:286-293. (Pubitemid 29055350)
55. Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease: results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med. 1998;243:495-500. (Pubitemid 28312246)
56. Demeure MJ, Klonoff CC, Karam JH, Duh QY, Clark OH. Insulinomas associated with multiple endocrine neo-plasia type 1: the need for a different surgical approach [with discussion]. Surgery. 1991;110:998-1005.
57. Lairmore TC, Chen VY, De Benedetti MK, Gillanders WE, Norton JA, Doherty GM. Duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg. 2000;231:909-918. (Pubitemid 30350250)
58. Jensen RT. Pancreatic endocrine tumors: recent advances. Ann Oncol. 1999;10(suppl 4):170-176.
59. Rasbach DA, van Heerden JA, Telander RL, Grant CS, Carney JA. Surgical management of hyperinsulinism in the multiple endocrine neoplasia, type 1 syndrome. Arch Surg. 1985;120:584-589. (Pubitemid 15053414)
60. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658-5671. (Pubitemid 33152604)
61. Akerström G, Hessman O, Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuro-endocrine tumors of the pancreas in MEN 1. Langenbecks Arch Surg. 2002;386:558-569. (Pubitemid 34285635)
62. O'Riordain DS, O'Brien T, van Heerden JA, Service FJ, Grant CS. Surgical management of insulinoma associated with multiple endocrine neoplasia type I [with discussion]. World J Surg. 1994;18:488-494. (Pubitemid 24273845)
63. Norton JA, Wells SA Jr. The surgical management of patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 1997;82:359-361.
64. Simon D, Starke A, Goretzki PE, Roeher HD. Reoperative surgery for organic hyperinsulinism: indications and operative strategy [with discussion]. World J Surg. 1998;22:666-672. (Pubitemid 28277859)
65. Lo CY, Lam KY, Fan ST. Surgical strategy for insuli-nomas in multiple endocrine neoplasia type I. Am J Surg. 1998;175:305-307.
66. Cougard P, Goudet P, Peix JL, et al. Insulinomas in multiple endocrine neoplasia type 1: report of a series of 44 cases by the multiple endocrine neoplasia study group [in French]. Ann Chir. 2000;125:118-123. (Pubitemid 30219760)
67. Sarmiento JM, Que FG, Grant CS, Thompson GB, Farnell MB, Nagorney DM. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach [with discussion]. Surgery. 2002;132:976-983. (Pubitemid 36026944)
68. Proye C, Pattou F, Carnaille B, Lefebvre J, Decoulx M, d'Herbomez M. Intraoperative insulin measurement during surgical management of insulinomas. World J Surg. 1998;22:1218-1224. (Pubitemid 28514340)
69. Turner RC, Lee EC, Morris PJ, Harris EA. Localization of insulinomas. Lancet. 1978;1:515-518.
70. Teichmann RK, Spelsberg F, Heberer G. Intraoperative biochemical localization of insulinomas by quick radioim-munoassay. Am J Surg. 1982;143:113-115. (Pubitemid 12149666)
71. Giudici F, Nesi G, Brandi ML, Tonelli F. Surgical management of insulinomas in multiple endocrine neoplasia type 1. Pancreas. In press.
72. Carneiro DM, Levi JU, Irvin GL III. Rapid insulin assay for intraoperative confrmation of complete resection of insulinomas [with discussion]. Surgery. 2002;132:937-943. (Pubitemid 36026939)
73. Larsson LI, Hirsch MA, Holst JJ, et al. Pancreatic somatostatinoma: clinical features and physiological implications. Lancet. 1977;1:666-668. (Pubitemid 8121565)
74. Lévy-Bohbot N, Merle C, Goudet P, et al (Groupe des Tumeurs Endocrines). Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol. 2004;28:1075-1081. (Pubitemid 39655853)
75. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25:458-511. (Pubitemid 38780668)
76. O'Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. Eur J Surg Oncol. 2008;34:324-332. (Pubitemid 351312867)
77. Howard TJ, Stabile BE, Zinner MJ, Chang S, Bhagavan BS, Passaro E Jr. Anatomic distribution of pancreatic endocrine tumors. Am J Surg. 1990;159:258-264. (Pubitemid 20057932)
78. Hodul PJ, Strosberg JR, Kvols LK. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? Cancer Control. 2008;15: 314-321.
79. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendo-crine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29-37. (Pubitemid 36759176)
80. Elias D, Lasser P, Ducreux M, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. 2003;133:375-382. (Pubitemid 36515325)
81. House MG, Cameron JL, Lillemoe KD, et al. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg. 2006;10:138-145. (Pubitemid 41820601)
82. Maithel SK, Fong Y. Hepatic ablation for neuroendocrine tumor metastases. J Surg Oncol. 2009;100:635-638.
83. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271-279.
84. Abood GJ, Go A, Malhotra D, Shoup M. The surgical and systemic management of neuroendocrine tumors of the pancreas. Surg Clin North Am. 2009;89:249-266, x.
85. Van Vilsteren FG, Baskin-Bey ES, Nagorney DM, et al. Liver transplantation for gastroenteropancreatic neuroen-docrine cancers: defning selection criteria to improve survival. Liver Transpl. 2006;12:448-456.